BioAge Doses First Patient in Phase 2 Trial for Diabetic Macular Edema Treatment
Event summary
- BioAge Labs dosed the first participant in its QUELL-DME Phase 2 trial for BGE-102, an oral NLRP3 inhibitor, in diabetic macular edema (DME).
- The trial will enroll approximately 180 patients, evaluating BGE-102 as monotherapy and in combination with anti-VEGF therapy.
- Primary endpoint is change in best-corrected visual acuity at week 12, with topline results expected in the second half of 2027.
- BGE-102 targets NLRP3, a key driver of inflammation in DME, aiming to reduce the need for repeated eye injections.
The big picture
BioAge’s QUELL-DME trial represents a strategic pivot toward inflammation-driven retinal diseases, leveraging its NLRP3 inhibitor platform. The shift aligns with broader industry trends toward oral therapies for chronic conditions, potentially reducing treatment burden for patients. Success in DME could position BioAge as a key player in ophthalmology, expanding beyond its cardiometabolic focus.
What we're watching
- Clinical Efficacy
- Whether BGE-102 can demonstrate superior visual acuity improvements compared to standard anti-VEGF therapy.
- Development Strategy
- How QUELL-DME results will inform BioAge’s approach to other NLRP3-driven retinal diseases, such as geographic atrophy.
- Market Differentiation
- The pace at which BioAge can position BGE-102 as a first-line oral treatment for DME, potentially disrupting the current injection-based standard.
Related topics